Neuroprotective Effect of Bone Marrow-Derived Mesenchymal Stem Cell Secretome in 6-OHDA-Induced Parkinson’s Disease

Abstract

Aim: The aim of the study was to evaluate the neuroprotective effect of bone marrow stem cell secretome in the 6-hydroxydopamine (6-OHDA) model of Parkinson's disease. Materials & methods: Secretome prepared from mesenchymal stem cells of 3-month-old rats was injected daily for 7 days between days 7 and 14 after 6-OHDA administration. After 14 days, various neurobehavioral parameters were conducted. These behavioral parameters were further correlated with biochemical and molecular findings. Results & conclusion: Impaired neurobehavioral parameters and increased inflammatory, oxidative stress and apoptotic markers in the 6-OHDA group were significantly modulated by secretome-treated rats. In conclusion, mesenchymal stem cells-derived secretome could be further explored for the management of Parkinson's disease.

Emerging role of mesenchymal stromal cells (MSCs)-derived exosome in neurodegeneration-associated conditions: a groundbreaking cell-free approach

“…Besides, BDNF improves the survival of DA neurons and sustains dopaminergic neurotransmission and motor function [231]. In other studies, neurobehavioral deficits, neuroinflammation, oxidative stress, and neural cell apoptosis were alleviated in the 6-OHDA murine model of PD following injections of MSCsderived exosome [232]. Further studies to clarify the corresponding mechanism behind the exosome-elicited anti-inflammatory and pro-survival effects on the PD animal model have conferred the key role of miR-188-3p [233].…”

Mesenchymal stem cell secretome and extracellular vesicles for neurodegenerative diseases: Risk-benefit profile and next steps for the market access

“…Multiple research teams have focused on utilizing MSC-secretome/EVs to develop novel therapeutic strategies for PD ( Table 4 ). The majority of studies have evaluated their efficacy in animal models of PD using 6-hydroxydopamine (6-OHDA) [ [101] , [102] , [103] , [104] , [105] ] and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MTPT) [ 106 ], with only one study using transgenic mice expressing human α-synuclein [ 107 ]. There have been no studies on the efficacy of MSC-secretome or EVs in humans.…”

Therapeutic utility of mesenchymal stromal cell (MSC)-based approaches in chronic neurodegeneration: a glimpse into underlying mechanisms, current status, and prospects

“…Further, in silico investigations recognized conceivable inhibitors of α-syn proteotoxicity, most importantly, growth factors [ 153 ]. In another study in the 6-OHDA-induced rat model of PD, MSC-derived secretome alleviated neurobehavioral deficits and reduced inflammation, oxidative stress, and apoptosis [ 154 ]. Further studies to elucidate the underlying mechanism behind the MSC-derived exosome-induced anti-inflammatory and anti-apoptotic effects in the PD rodent model highlighted the importance of miR-188-3p [ 155 ].…”